(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP ...

Caela Shay left Verily to lead U.S. communications at ResMed. Astellas Pharma announced chief medical officer Tadaaki Taniguchi, MD, PhD moved to a newly created position of chief research and ...

TOKYO, Feb. 4, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective ...

Astellas Pharma has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare seeking conditional approval of avacincaptad pegol intravitreal solution (ACP ...

The role will oversee the integration of the pharma’s research and development teams in order to “provide the next-generation groundbreaking therapies from Astellas,” the company explained.

We have these four representatives here. Hello, everyone. I am Atsushi Kitamura from Astellas Pharma Inc. Thank you very much for joining our FY 2024 third quarter year-to-date financial results ...

Astellas Pharma Inc., a global life sciences company committed to turning innovative science into VALUE for patients, announced the submission of a New Drug Application (NDA) to Japan’s Ministry of ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic atrophy (GA) med Izervay has taken a few beatings in recent months.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Shares of Astellas Pharma stock opened at $9.78 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.10 and a quick ratio of 0.86. The business has a fifty day simple ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...